Hair care and Anti-hair loss composition and use thereof

Abstract

A hair care and anti-hair loss composition, the composition comprising cationic hyaluronic acid and ergothioneine, and the mass ratio of the cationic hyaluronic acid to ergothioneine being 1: 0.2-5. The composition can promote the secretion of a vascular endothelial growth factor (VEGF), and has the effects of hair care, hair loss prevention, and hair growth promotion.

Description

A hair care and anti-hair loss composition and its application

[0001] This invention claims priority to Chinese Patent Application No. 202411864059.5, filed on December 17, 2024, entitled “A Hair Care and Anti-Hair Loss Composition and Its Application”, the entire contents of which are incorporated herein by reference. Technical Field

[0002] This invention relates to a hair care and anti-hair loss composition, and also to the application of the composition in the fields of anti-hair loss and hair care. Background Technology

[0003] As we age or due to certain medical conditions, hair gradually thins and falls out. In recent years, hair loss has shown a trend of affecting younger people. Hair loss is often related to a variety of factors, such as genetics, hormonal imbalances, malnutrition, and excessive psychological stress. To address hair loss, it's essential to maintain a healthy lifestyle and avoid excessive use of chemical products such as hair dyes and perms on the hair and scalp. Furthermore, medications and topical treatments can help reduce hair loss and promote hair growth. In short, solving hair loss requires addressing the specific causes and treatments accordingly. Only in this way can one achieve healthy, thick hair.

[0004] Dermal papilla cells are located at the root of the hair follicle. During the hair growth phase, these cells proliferate rapidly and provide nutrients for hair growth. Vascular endothelial growth factor (VEGF) within the dermal papilla cells plays a crucial role in nutrient supply, effectively promoting capillary formation. Increased VEGF levels provide richer nutrients to the hair follicle, promoting dermal papilla cell proliferation and thus strengthening hair and promoting hair growth. The androgen DHT inhibits cell growth, leading to a reduced ability of cells to secrete VEGF, thereby affecting normal hair growth. Therefore, increasing the secretion of VEGF by cells is also an effective way to promote hair growth. Summary of the Invention

[0005] The purpose of this invention is to provide a hair care and anti-hair loss composition containing cationic hyaluronic acid. Experiments have verified that cationic hyaluronic acid has a synergistic effect in promoting hair growth. This composition combines ergothioneine with cationic hyaluronic acid, exhibiting a synergistic effect in promoting the secretion of vascular endothelial growth factor (VEGF).

[0006] A hair care and anti-hair loss composition comprising cationic hyaluronic acid, wherein the cationic hyaluronic acid may be one type, or two or more types.

[0007] Furthermore, the composition also includes ergothioneine.

[0008] Furthermore, the mass ratio of cationic hyaluronic acid to ergothionein in the composition is 1:0.2-5.

[0009] Furthermore, the composition also includes pharmaceutically acceptable excipients.

[0010] Furthermore, the composition also includes cosmetic-acceptable excipients and / or active ingredients.

[0011] This invention also provides the application of cationic hyaluronic acid in the preparation of products that promote the secretion of vascular endothelial growth factor (VEGF).

[0012] This invention also provides the application of the combination of cationic hyaluronic acid and ergothionein in the preparation of products that promote the secretion of vascular endothelial growth factor (VEGF).

[0013] The present invention also provides the use of cationic hyaluronic acid and / or combinations of cationic hyaluronic acid and ergothioneine and / or the above-mentioned hair care and anti-hair loss compositions in the preparation of hair care, anti-hair loss and / or hair growth promotion products.

[0014] The present invention also provides a method for hair care and / or hair loss prevention and / or hair growth promotion, comprising administering cationic hyaluronic acid or the above-described hair care and hair loss prevention composition to a subject.

[0015] Experimental verification of this invention has revealed that in a model of dermal papilla cells stimulated by the androgen DHT, cationic hyaluronic acid and the combination of ergothioneine and cationic hyaluronic acid have significant synergistic effects in promoting the increase of vascular endothelial growth factor (VEGF) content, showing potential application value in anti-hair loss, hair care, or hair growth promotion products. Detailed Implementation

[0016] The present application is further illustrated below with reference to embodiments. It should be understood that the embodiments are only used to further illustrate and explain the present application and are not intended to limit the present application.

[0017] Unless otherwise defined, technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art. While similar or identical methods and materials may be used in experimental or practical applications, materials and methods are described herein. In case of conflict, the definitions included herein shall prevail. Furthermore, materials, methods, and examples are for illustrative purposes only and are not intended to be limiting. The present application is further described below with reference to specific embodiments, but is not intended to limit the scope of the application.

[0018] This invention provides a hair care and anti-hair loss composition, wherein the active ingredient in the composition contains cationic hyaluronic acid.

[0019] Cationic hyaluronic acid, also known as hydroxypropyltrimethylammonium chloride hyaluronic acid, is formed by grafting hydroxypropyltrimethylammonium chloride onto hyaluronic acid through a chemical grafting process and can be purchased directly from the market. Cationic hyaluronic acid retains the natural moisturizing properties of hyaluronic acid, providing long-lasting hydration for skin and hair. In addition, the positive charge in cationic hyaluronic acid combines with the negative charge in hair, giving it antistatic properties.

[0020] Experiments have shown that cationic hyaluronic acid, compared with a physical mixture of pure hyaluronic acid and hydroxypropyltrimethylammonium chloride, exhibits a superior effect in promoting the secretion of vascular endothelial growth factor (VEGF), demonstrating a significant synergistic effect.

[0021] Furthermore, there are no special requirements for the content of cationic hyaluronic acid in the composition, as long as it can promote the secretion of vascular endothelial growth factor (VEGF). In a specific embodiment of the present invention, the content of cationic hyaluronic acid in the composition is 0.1wt%-0.6wt%, for example, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, or 0.6%.

[0022] In a specific embodiment of the present invention, the molecular weight of the cationic hyaluronic acid is 50kDa-1500kDa, for example 50kDa, 100kDa, 150kDa, 200kDa, 250kDa, 300kDa, 350kDa, 400kDa, 450kDa, 500kDa, 550kDa, 600kDa, 650kDa, 700kDa, 750kDa, 800kDa, 850kDa, 900kDa, 950kDa, 1000kDa, 1050kDa, 1100kDa, 1150kDa, 1200kDa, 1250kDa, 1300kDa, 1350kDa, 1400kDa, 1450kDa, and 1500kDa.

[0023] In one specific embodiment of the present invention, the degree of substitution of cationic hyaluronic acid is 1-40 wt%, for example, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, and 40%.

[0024] Furthermore, the active ingredient in the above composition also includes ergothioneine. Experimental results have shown that the combination of ergothioneine and cationic hyaluronic acid exhibits a more significant synergistic effect.

[0025] Ergothioneine (EGT) is a common antioxidant that, in addition to its excellent antioxidant activity, also has anti-inflammatory and skin-whitening effects.

[0026] In one specific embodiment of the present invention, ergothioneine is introduced in pure form.

[0027] In one specific embodiment of the present invention, the mass ratio of cationic hyaluronic acid to ergothioneine is 5:1 to 1:5, for example, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, or 1:5.

[0028] Furthermore, there are no special requirements for the content of cationic hyaluronic acid and ergothioneine in the composition, as long as they can promote the secretion of vascular endothelial growth factor (VEGF). In a specific embodiment of the present invention, the total content of cationic hyaluronic acid and ergothioneine in the composition is 0.1 wt%-0.6 wt%, for example, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, or 0.6%.

[0029] In a specific embodiment of the present invention, in addition to cationic hyaluronic acid and ergothioneine, the above composition also includes pharmaceutically acceptable excipients, such as excipients, solubilizers, cosolvents, sustained-release agents, stabilizers, pH adjusters, solvents, etc. required for the preparation of various dosage forms.

[0030] In one specific embodiment of the present invention, in addition to cationic hyaluronic acid and ergothioneine, the above composition also includes cosmetic-acceptable excipients and / or other active ingredients.

[0031] Furthermore, the acceptable excipients in the cosmetics include, but are not limited to, one or more of the following: preservatives, fragrances, thickeners, solubilizers, oils, solvents, pH adjusters, etc.

[0032] Furthermore, the other active ingredients can be those commonly used in the cosmetics industry, such as moisturizing ingredients, anti-inflammatory ingredients, antioxidant ingredients, hair care ingredients, and anti-hair loss ingredients. The addition of these active ingredients will not affect the effects of cationic hyaluronic acid and ergothioneine in promoting the secretion of vascular endothelial growth factor (VEGF).

[0033] Furthermore, the composition is a topical product, which can be a medicine or a cosmetic for hair care or hair loss prevention. It can be formulated into various dosage forms, such as conditioner, shampoo, spray, drops, ointment, etc.

[0034] This invention also provides the application of cationic hyaluronic acid in the preparation of products that promote the secretion of vascular endothelial growth factor (VEGF).

[0035] This invention also provides the application of cationic hyaluronic acid in the preparation of hair care, hair loss prevention and / or hair growth promotion products.

[0036] This invention also provides the application of the combination of cationic hyaluronic acid and ergothionein in promoting the secretion of vascular endothelial growth factor (VEGF).

[0037] This invention also provides the use of a combination of cationic hyaluronic acid and ergothioneine in the preparation of hair care, hair loss prevention and / or hair growth promotion products.

[0038] Furthermore, in the combination of cationic hyaluronic acid and ergothioneine, the mass ratio of cationic hyaluronic acid to ergothioneine is 1:0.2-5.

[0039] The present invention also provides the use of the hair care and anti-hair loss composition in the preparation of hair care, anti-hair loss and / or hair growth promotion products.

[0040] Furthermore, the hair care, hair loss prevention, and / or hair growth promotion products are pharmaceuticals or cosmetics.

[0041] The present invention also provides a method for hair care and / or hair loss prevention and / or hair growth promotion, comprising administering cationic hyaluronic acid or the above-described hair care and hair loss prevention composition to a subject.

[0042] Example

[0043] This invention provides a general and / or specific description of the materials and experimental methods used in the experiments. In the following examples and comparative examples, unless otherwise specified, % represents wt%, i.e., weight percentage. Reagents or instruments used, unless otherwise specified, are all commercially available conventional reagent products.

[0044] Cationic hyaluronic acid with a molecular weight of 200kDa and a degree of substitution of 10% is from Bloomage Biotechnology.

[0045] Ergothioneine: from Bloomage Biotech.

[0046] Hyaluronic acid: from Bloomage Biotech.

[0047] Example 1

[0048] 1. Experimental Samples:

[0049] 2% minoxidil solution: Minoxidil finished product purchased directly (active ingredient concentration of 2%).

[0050] 6% cationic hyaluronic acid solution: Weigh 0.6g of cationic hyaluronic acid, dissolve it in 10mL of PBS, and mix well.

[0051] 6% hyaluronic acid + hydroxypropyltrimethylammonium chloride (molar ratio 10:1) solution: Weigh 0.58g of hyaluronic acid with a molecular weight of 200kDa (from Bloomage Biotech) and 0.02g of hydroxypropyltrimethylammonium chloride, dissolve in 10mL of PBS, and mix well to obtain the solution.

[0052] 2. Collect human dermal papilla cells in the logarithmic growth phase (BNCC360091, Beina Biotechnology), at a cell density of 1×10⁻⁶. 5 Inoculate one well per well into a 24-well plate.

[0053] 3. Sample loading: After incubation in an incubator (37℃, 5% CO2) for 24 hours, tests were conducted according to the groupings in Table 1. The DHT stimulation model construction process is as follows: 1×10 5 Cells were seeded at a density of cells / well into 24-well plates and incubated overnight in an incubator (37°C, 5% CO2). When the cell deposition rate in the 24-well plates reached 40%–60%, 800 μL of cell culture medium was added to all groups. 100 μL of 10×DHT working solution (concentration 10 μg / mL) was added to all groups except the blank control group. Then, 200 μL of PBS was added to the blank control group, 100 μL of PBS was added to the negative control group, 100 μL of 2% minoxidil solution was added to the positive control group, 100 μL of 6% cationic hyaluronic acid solution was added to experimental group 1, and 100 μL of 6% hyaluronic acid + hydroxypropyltrimethylammonium chloride (molar ratio 10:1) solution was added to experimental group 2. After sample addition, the plates were shaken left and right to mix the drugs. Three replicates were set for each group. In the positive control group, the final concentration of minoxidil was 0.2%; in experimental group 1, the final concentration of cationic hyaluronic acid was 0.6%; and in experimental group 2, the final total concentration of hyaluronic acid and hydroxypropyltrimethylammonium chloride was 0.6%.

[0054] Table 1 Experimental conditions and grouping

[0055] 4. Sample collection: After adding the sample, continue to incubate in an incubator (37℃, 5% CO2) for 24 hours and collect the culture medium.

[0056] 5. Detection: The VEGF content in the culture medium was detected using a human VEGF ELISA kit. The specific detection method was performed according to the instructions in the kit.

[0057] 6. Data Analysis and Test Results

[0058] The data obtained was statistically analyzed using the t-test method, and the results are shown in Table 2 below:

[0059] Table 2 VEGF content (pg / mL)

[0060] Note: When performing statistical analysis using the t-test method, significance compared to the BC group is indicated by #, with P-value < 0.05 indicated by #, P-value < 0.01 indicated by ##, and P-value < 0.001 indicated by ###; compared to the NC group, significance is indicated by *, with P-value < 0.05 indicated by *, P-value < 0.01 indicated by **, and P-value < 0.001 indicated by ***. Compared to the cationic hyaluronic acid group, significance is indicated by ▲, with P-value < 0.05 indicated by ▲, and P-value < 0.01 indicated by ▲▲.

[0061] As shown in Table 2, compared with the negative control group, cationic hyaluronic acid and the physical mixture of hyaluronic acid and hydroxypropyltrimethylammonium chloride, at a dosage concentration of 0.6% (m / v), all significantly promoted vascular endothelial growth factor (VEGF) synthesis in dermal papilla cells. Compared with the physical mixture of hyaluronic acid and hydroxypropyltrimethylammonium chloride, cationic hyaluronic acid synthesized via chemical grafting showed a more significant effect in promoting VEGF synthesis (p<0.01), demonstrating that cationic hyaluronic acid has a synergistic effect in promoting hair growth.

[0062] Example 2

[0063] 1. Experimental Samples:

[0064] Preparation of 2% minoxidil solution: Purchase minoxidil product directly (active ingredient concentration of 2%).

[0065] 6% cationic hyaluronic acid solution: Weigh 0.6g of cationic hyaluronic acid, dissolve it in 10mL of PBS, and mix well.

[0066] Preparation of 6% ultrapure ergothioneine: Weigh 0.6g of ultrapure ergothioneine, dissolve it in 10mL of PBS, and mix well.

[0067] 6% cationic hyaluronic acid + ergothioneine solution: Cationic hyaluronic acid and ultrapure ergothioneine were weighed at mass ratios of 10:1, 5:1, 1:1, 1:5, and 1:10, respectively, with a total mass of 0.6g for both. They were then dissolved in 10mL of PBS and mixed thoroughly to obtain cationic hyaluronic acid + ergothioneine solutions with different mass ratios.

[0068] 2. Collect human dermal papilla cells in the logarithmic growth phase, at a cell density of 1×10⁻⁶. 5 Inoculate one well per well into a 24-well plate.

[0069] 3. Sample loading: After incubation in an incubator (37℃, 5% CO2) for 24 hours, tests were conducted according to the groupings in Table 3. The DHT stimulation model construction process is as follows: 1×10 5 Cells were seeded at a density of cells / well into 24-well plates and incubated overnight in an incubator (37°C, 5% CO2). When the cell deposition rate in the 24-well plates reached 40%–60%, 800 μL of cell culture medium was added to all groups. 100 μL of 10×DHT working solution (concentration 10 μg / mL) was added to all groups except the blank control group. Then, 200 μL of PBS was added to the blank control group, 100 μL of PBS was added to the negative control group, 100 μL of 2% minoxidil solution was added to the positive control group, 100 μL of 6% ergothioneine solution was added to experimental group 1, and 100 μL of 6% cationic hyaluronic acid solution was added to experimental group 2. Group 3 was treated with 100 μL of a 6% cationic hyaluronic acid + ergothioneine (mass ratio 10:1) solution; Group 4 with 100 μL of a 6% cationic hyaluronic acid + ergothioneine (mass ratio 5:1) solution; Group 5 with 100 μL of a 6% cationic hyaluronic acid + ergothioneine (mass ratio 1:1) solution; Group 6 with 100 μL of a 6% cationic hyaluronic acid + ergothioneine (mass ratio 1:5) solution; and Group 7 with 100 μL of a 6% cationic hyaluronic acid + ergothioneine (mass ratio 1:10) solution. After adding the samples, the well plates were shaken left and right to mix the drugs evenly. Each group had three replicates. In the positive control group, the final concentration of minoxidil was 0.2%; in experimental group 1, the final concentration of ergothioneine was 0.6%; in experimental group 2, the final concentration of cationic hyaluronic acid was 0.6%; and in experimental groups 3-7, the final total concentration of cationic hyaluronic acid and ergothioneine was 0.6%.

[0070] Table 3 Experimental conditions and grouping

[0071] 4. Sample collection: After adding the sample, continue to incubate in an incubator (37℃, 5% CO2) for 24 hours and collect the culture medium.

[0072] 5. Detection: The VEGF content in the culture medium was detected using a human VEGF ELISA kit. The specific detection method was performed according to the instructions in the kit.

[0073] 6. Data Analysis and Test Results

[0074] The data obtained was statistically analyzed using the t-test method, and the results are shown in Table 4 below:

[0075] Table 4. VEGF content (pg / mL)

[0076] Note: When performing statistical analysis using the t-test method, significance compared to the BC group is indicated by #, with P-value < 0.05 as #, P-value < 0.01 as ##, and P-value < 0.001 as ###; compared to the NC group, significance is indicated by *, with P-value < 0.05 as *, P-value < 0.01 as **, and P-value < 0.001 as ***. Compared to the ergothioneine group, significance is indicated by ▲, with P-value < 0.05 as ▲ and P-value < 0.01 as ▲▲. Compared to the cationic hyaluronic acid group, significance is indicated by ▼, with P-value < 0.05 as ▼ and P-value < 0.01 as ▼▼.

[0077] As shown in Table 4, compared with the negative control group, the combination of cationic hyaluronic acid and ergothioneine in ratios of 10:1, 5:1, 1:1, 1:5, and 1:10 all significantly promoted the growth of vascular endothelial growth factor (VEGF) in dermal papilla cells. The combination of cationic hyaluronic acid and ergothioneine in a 1:5:5:1 ratio showed significant differences compared with the single components, indicating that the composition synergistically promoted VEGF, thus exhibiting a synergistic effect in promoting hair growth.

[0078] The above description is merely an embodiment of the present invention, and the scope of protection of the present invention is not limited to these specific embodiments, but is determined by the claims of the present invention. For those skilled in the art, the present invention can have various modifications and variations. Any modifications, equivalent substitutions, improvements, etc., made within the technical concept and principle of the present invention should be included within the scope of protection of the present invention.

Claims

1. A composition characterized in that, The composition comprises the following components: a) At least one cationic hyaluronic acid; b) At least one ergothioneine.

2. The composition of claim 1, wherein, The mass ratio of components a) and b) is 1:0.2-5.

3. The composition according to claim 1 or 2, characterized in that, It also includes acceptable excipients.

4. Application of cationic hyaluronic acid in the preparation of products that promote the secretion of vascular endothelial growth factor (VEGF).

5. Application of cationic hyaluronic acid in the preparation of hair care and / or anti-hair loss and / or hair growth promotion products.

6. Application of cationic hyaluronic acid and ergothionein in the preparation of products that promote the secretion of vascular endothelial growth factor (VEGF).

7. Use according to claim 6, characterized in that, The mass ratio of cationic hyaluronic acid to ergothioneine is 1:0.2-5.

8. Use of the composition of any one of claims 1-3 in the preparation of hair care and / or hair loss prevention and / or hair growth promotion products.

9. A method for hair care and / or preventing hair loss and / or promoting hair growth, comprising administering cationic hyaluronic acid or the composition of any one of claims 1-3 to a subject.

Images